# Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)
Canonical URL: https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-to-acquire-optinose-creating-significant-commercial-expansion-opportunities-for-xhancer-in-chronic-rhinosinusitis-crs
Ticker: PRTK
Company: Paratek Pharmaceuticals
Source: Paratek Pharmaceuticals
Published: 2025-03-19 21:25 EST
Original Source URL: https://www.pressviewer.com
## Summary

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><ul><li style="text-align:left;"><em>Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10</em><em> </

## Article Body
Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10 million patient market

Acquisition advances Paratek's vision to become a multi-product company focused on...
## Recent Company News
- 2026-04-16 07:30 EST — [Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2026](https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-to-present-new-data-on-nuzyrar-omadacycline-at-escmid-global-2026) — Source: Paratek Pharmaceuticals
- 2026-03-18 07:00 EST — [Paratek Pharmaceuticals Completes Combination with Radius Health, Expanding Its Multi-Product Specialty Commercial Platform](https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-completes-combination-with-radius-health-expanding-its-multi-product-specialty-commercial-platform) — Source: Paratek Pharmaceuticals
- 2026-02-24 07:30 EST — [Paratek Pharmaceuticals Announces Positive Results for NUZYRA® Therapeutic Efficacy Studies in Inhalation Anthrax Triggering Additional Procurement under BARDA Project BioShield Contract](https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-announces-positive-results-for-nuzyrar-therapeutic-efficacy-studies-in-inhalation-anthrax-triggering-additional-procurement-under-barda-project-bioshield-contract) — Source: Paratek Pharmaceuticals
- 2025-10-17 07:30 EST — [Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at IDWeek 2025 and CHEST 2025](https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-to-present-new-data-on-nuzyrar-omadacycline-at-idweek-2025-and-chest-2025) — Source: Paratek Pharmaceuticals
- 2025-05-21 08:26 EST — [Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies](https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-completes-acquisition-of-optinose-creating-an-expanded-portfolio-of-specialty-therapies) — Source: Paratek Pharmaceuticals
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)